A First in Man Randomized Placebo Controlled Study of Single Ascending Intravenous Doses of NI-0701 in Healthy Volunteers
Latest Information Update: 09 Jun 2022
At a glance
- Drugs NI 0701 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Light Chain Bioscience
- 14 Dec 2010 New trial record